SCHEMBL6919146

SCHEMBL6919146

CCCCOc1c(Nc2ccc(C#N)cc2)nc(C(C)(C)C)nc1-c1ccc(C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.44
HPGD P15428 5/20 0.44
GAA P10253 2/20 0.44
MAPKAPK2 P49137 1/20 0.37
ALDH1A1 P00352 4/20 0.36
HSD17B10 Q99714 1/20 0.36
F9 P00740 1/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ABCB1 P08183 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.36
KDM1A O60341 1/20 0.35
RXFP1 Q9HBX9 2/20 0.35
THRB P10828 1/20 0.35
CDK1 P06493 1/20 0.35
KDR P35968 1/20 0.35
CSNK1A1 P48729 1/20 0.34
CSNK1D P48730 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6919786 0.81 HTR2A (0.41) KDM4EHPGDGAAMAPKAPK2KDM1A
SCHEMBL1232626 0.79 F9 (0.48) MAPKAPK2ALDH1A1F9RXFP1THRB
SCHEMBL6917915 0.71 KDM4E (0.44) KDM4EHPGDGAAALDH1A1HSD17B10
SCHEMBL6919788 0.71 F9 (0.42) KDM4EHPGDGAAALDH1A1F9
SCHEMBL6919971 0.69 F9 (0.48) GAAALDH1A1F9L3MBTL1MEN1
SCHEMBL6919662 0.68 ABCG2 (0.55) KDM4EALDH1A1ABCB1ABCG2KDM1A
SCHEMBL1232774 0.68 F9 (0.53) KDM4EMAPKAPK2F9MEN1KMT2A
SCHEMBL6917911 0.68 ABCG2 (0.48) KDM4EHPGDGAAALDH1A1HTT
SCHEMBL1232542 0.65 F9 (0.74) MAPKAPK2ALDH1A1F9ABCG2RXFP1
SCHEMBL7918523 0.64 MAPT (0.61) GAAALDH1A1HTTL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462123-B1 4,5,6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2013-10-02 EP disclosed
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2012-05-31 US disclosed
WO-2011017296-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS SCHERING CORPORATION (US) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS F9, F8, F12 KDM4E 1014/4885HPGD 517/4885GAA 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.